Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Wayfair Inc (W) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Wayfair Inc — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.85 (market cap $4.49B), while Wayfair Inc trades at $85.99 (market cap $12.31B). The key difference: Wayfair Inc is far larger — about 2.7× ACADIA Pharmaceuticals Inc.'s market cap, and ACADIA Pharmaceuticals Inc. is trading nearer its 52-week high, Wayfair Inc nearer its low. Which is the better fit depends on your goals.
| ACAD | W | |
|---|---|---|
Market Cap | $4.49B | $12.31B |
Sector | Health | Consumer Cyclical |
52-Week High | $28.06 | $119.05 |
52-Week Low | $20.06 | $53.37 |
Enterprise Value | $3.69B | $14.88B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
Wayfair (W) trades at $93.18, down 1.4% today, with a bullish technical outlook supported by moving averages and positive momentum indicators. The company shows mixed fundamentals with strong revenue growth to $12.46B in 2025 but negative net income margins of -2.41%. Recent analyst upgrades to Strong Buy highlight optimism around earnings potential, though high debt levels and competitive pressures remain concerns.
Investment outlook balances strong analyst support (52% buy ratings) against fundamental challenges including negative profitability and elevated debt. The stock offers momentum potential with upcoming Q2 earnings on August 4, 2026 as a key catalyst, but requires careful monitoring of margin improvement and debt management for sustained growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Wayfair Inc
Wayfair is a global leader in home goods, operating a massive digital marketplace that connects millions of consumers with thousands of suppliers. It utilizes an asset-light, inventory-light model combined with a proprietary logistics network (CastleGate) and an accelerating brick-and-mortar presence to deliver an end-to-end shopping experience for everything from decor to full home renovations.
Read more on W →
